TUDORZA PRESSAIR
Peakaclidinium bromide
NDAINHALATIONPOWDER, METERED
Approved
Jul 2012
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Clinical Trials (5)
A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants
Started Oct 2021
20 enrolled
Healthy Volunteers
To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease
Started Dec 2017
0Chronic Obstructive Pulmonary Disease
Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Started Nov 2017
20 enrolled
Pulmonary Disease, Chronic Obstructive
Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints
Started Mar 2017
26,839 enrolled
Pulmonary Disease, Chronic Obstructive
Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients
Started Feb 2017
1,625 enrolled
COPD
Loss of Exclusivity
LOE Date
Mar 13, 2029
36 months away
Patent Expiry
Mar 13, 2029